KRAS and neoplasm: Among patients with vtKRAS, patients with G12 KRAS variants were more likely than those with non-G12 KRAS variants to have elevated γ-glutamyltransferase levels (63 of 99 [64%] vs 9 of 28 [32%]; P = .003), large tumor size (57 of 99 [58%] vs 8 of 28 [29%]; P = .007), and lymphatic metastasis (19 of 99 [19%] vs 0; P = .01).